Patents by Inventor Clinton J. Dahlberg
Clinton J. Dahlberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220296552Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting meyloperoxidase activity.Type: ApplicationFiled: February 7, 2022Publication date: September 22, 2022Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
-
Patent number: 11331363Abstract: Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent.Type: GrantFiled: October 8, 2019Date of Patent: May 17, 2022Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Wei Gao, Mohan Kaadige, Sheryl Krig, Xiaolan Kou, Zhe Khang, Joseph Ou
-
Patent number: 11241406Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting myeloperoxidase activity.Type: GrantFiled: August 28, 2016Date of Patent: February 8, 2022Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
-
Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
Patent number: 11122832Abstract: A weight loss system is presented herein. In one embodiment, the weight loss system that accelerates weight loss in a subject eating a caloric restricted diet with a minimum daily protein intake of about 3 oz. and engaging in daily physical activity equivalent to about 5,000 steps per day is presented. The weight loss system can comprise an effective amount of: an antimicrobial component that includes berberine, cinnamon and curcumin; fish oil; a probiotic component that includes Lactobacillus spp., Bifidobacterium spp., and Streptococcus spp.; an antioxidant, phytochemical component that includes apple extract, grape extract, green tea extract, and olive extract; and a vitamin component that includes vitamins A, B, C, D, and E. The weight loss system can stimulate a weight loss of at least 3% more than if not administered to the subject. Further presented herein is a method of facilitating weight loss in a subject and a method of improving the health of a subject participating in a weight loss program.Type: GrantFiled: March 6, 2017Date of Patent: September 21, 2021Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Joseph Lamb, Joseph J. Ou, Sarah Elison, Wei Gao, Mohan Kaadige, Holly Brabazon -
Publication number: 20210038656Abstract: A detoxification system can include an effective amount of a probiotic component and a fiber component in combination with a circulation enhancing component, a high-protein meal replacement component, or both. The detoxification system increases urinary heavy metal excretion, decreases a fecal zonulin level, decreases a fecal calprotectin level, decreases a serum lipopolysaccharide binding protein (LBP) level, increases at least one of a salivary nitrite level and a serum arginine level, or a combination thereof in a subject as compared to a baseline level prior to administration of the detoxification system in an effective dosing regimen.Type: ApplicationFiled: November 5, 2018Publication date: February 11, 2021Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Joseph Lamb, Joseph J. Ou, Veera R. Konda, Sarah Elison, Wei Gao, Jay Bhandari
-
Publication number: 20200246412Abstract: Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent.Type: ApplicationFiled: October 8, 2019Publication date: August 6, 2020Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Wei Gao, Mohan Kaadige, Sheryl Krig, Xiaolan Kou, Zhe Khang, Joseph Ou
-
Patent number: 10434131Abstract: Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent.Type: GrantFiled: March 16, 2016Date of Patent: October 8, 2019Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Wei Gao, Mohan Kaadige, Sheryl Krig, Xiaolan Kou, Zhe Khang, Joseph Ou
-
METHODS AND COMPOSITIONS TO IMPROVE WEIGHT LOSS AND CARDIOMETABOLIC HEALTH BEYOND DIET AND EXCERCISE
Publication number: 20190261669Abstract: A weight loss system is presented herein. In one embodiment, the weight loss system that accelerates weight loss in a subject eating a caloric restricted diet with a minimum daily protein intake of about 3 oz. and engaging in daily physical activity equivalent to about 5,000 steps per day is presented. The weight loss system can comprise an effective amount of: an antimicrobial component that includes berberine, cinnamon and curcumin; fish oil; a probiotic component that includes Lactobacillus spp., Bifidobacterium spp., and Streptococcus spp.; an antioxidant, phytochemical component that includes apple extract, grape extract, green tea extract, and olive extract; and a vitamin component that includes vitamins A, B, C, D, and E. The weight loss system can stimulate a weight loss of at least 3% more than if not administered to the subject. Further presented herein is a method of facilitating weight loss in a subject and a method of improving the health of a subject participating in a weight loss program.Type: ApplicationFiled: March 6, 2017Publication date: August 29, 2019Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Joseph Lamb, Joseph J. Ou, Sarah Elison, Wei Gao, Mohan Kaadige, Holly Brabazon -
Patent number: 10343977Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.Type: GrantFiled: November 27, 2017Date of Patent: July 9, 2019Assignee: KINDEX PHARMACEUTICALS, INC.Inventors: Veera Konda, Jan Urban, Anuradha Desai, Clinton J. Dahlberg, Brian J. Carroll
-
Patent number: 10179155Abstract: Phosphodiesterase-4 (PDE4) inhibiting compositions comprising a Sceletium and an activity enhancer are disclosed and described. Methods and systems for inhibiting PDE4, as well as, dosage forms comprising a Sceletium extract and an activity enhancer are also disclosed. Additionally disclosed are methods for enhancing the potency or PDE4 inhibitory activity of a Sceletium extract by addition of an activity enhancer.Type: GrantFiled: February 26, 2015Date of Patent: January 15, 2019Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish
-
Publication number: 20180297934Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.Type: ApplicationFiled: November 27, 2017Publication date: October 18, 2018Inventors: Veera KONDA, Jan URBAN, Anuradha DESAI, Clinton J. DAHLBERG, Brian J. CARROLL
-
Publication number: 20180263944Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting meyloperoxidase activity.Type: ApplicationFiled: August 28, 2016Publication date: September 20, 2018Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
-
Patent number: 9828331Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.Type: GrantFiled: January 9, 2015Date of Patent: November 28, 2017Assignee: KINDEX PHARMACEUTICALS, INC.Inventors: Veera Konda, Jan Urban, Anuradha Desai, Clinton J. Dahlberg, Brian J. Carroll
-
Publication number: 20170065653Abstract: Phosphodiesterase (PDE) such as phosphodiesterase type V (PDE5) inhibiting compositions comprising a Sceletium extract are disclosed and described. Methods and systems for inhibiting PDE, as well as, dosage forms comprising a Sceletium extract are also disclosed. Additionally disclosed are methods for enhancing the potency or PDE inhibitory activity of a Sceletium extract by addition of an activity enhancer.Type: ApplicationFiled: February 26, 2015Publication date: March 9, 2017Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish
-
Publication number: 20170065652Abstract: Phosphodiesterase-4 (PDE4) inhibiting compositions comprising a Sceletium and an activity enhancer are disclosed and described. Methods and systems for inhibiting PDE4, as well as, dosage forms comprising a Sceletium extract and an activity enhancer are also disclosed. Additionally disclosed are methods for enhancing the potency or PDE4 inhibitory activity of a Sceletium extract by addition of an activity enhancer.Type: ApplicationFiled: February 26, 2015Publication date: March 9, 2017Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish
-
Publication number: 20170020948Abstract: Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent.Type: ApplicationFiled: March 16, 2016Publication date: January 26, 2017Applicant: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Wei Gao, Mohan Kaadige, Sheryl Krig, Xiaolan Kou, Zhe Khang, Joseph Ou
-
Publication number: 20150119461Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.Type: ApplicationFiled: January 9, 2015Publication date: April 30, 2015Inventors: Veera KONDA, Jan URBAN, Anuradha DESAI, Clinton J. DAHLBERG, Brian J. CARROLL
-
Patent number: 8829056Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.Type: GrantFiled: March 18, 2013Date of Patent: September 9, 2014Assignee: Kindex Pharmaceuticals, Inc.Inventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban
-
Patent number: 8410179Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.Type: GrantFiled: March 14, 2012Date of Patent: April 2, 2013Assignee: KinDex Therapeutics, LLCInventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban
-
Patent number: 8410178Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.Type: GrantFiled: October 28, 2011Date of Patent: April 2, 2013Assignee: KinDex Therapeutics, LLCInventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban